Can Biologics Be Discontinued in Patients with Psoriatic Arthritis in Stable Remission? A Prospective Single-CenterClinical and Ultrasound Study

Table 2

Cox regression analysis for factors potentially affecting the time to relapse after drug discontinuation.

		Relapse risk
		HR (95% CI)	value
Gender	Female vs. male	0.90 (0.44–1.86)	0.784
BMI	≥25 vs. <25	0.99 (0.93–1.06)	0.852
Age		1.00 (0.98–1.03)	0.845
Psoriasis duration		0.99 (0.97–1.02)	0.738
Spondylitis	Yes vs. no	1.05 (0.25–4.39)	0.945
Duration of remission	>5 vs. ≤5	1.40 (0.74–2.67)	0.298
Family history of psoriasis/PsA	Yes vs. no	0.74 (0.39–1.44)	0.381
Dyslipidemia	Yes vs. no	1.04 (0.46–2.37)	0.919
Obesity	Yes vs. no	1.24 (0.57–2.70)	0.591
Hypertension	Yes vs. no	1.46 (0.77–2.78)	0.246
Ischemic heart disease	Yes vs. no	2.17 (0.83–5.69)	0.116
Ultrasound nonalcoholic fatty liver	Yes vs. no	0.80 (0.42–1.53)	0.500
Peripheral arterial disease	Yes vs. no	3.56 (0.46–27.56)	0.225
Autoimmune thyroiditis	Yes vs. no	2.91 (0.38–22.62)	0.304
Depression	Yes vs. no	0.77 (0.18–3.24)	0.720
VAS pain TP0	Yes vs. no	1.00 (0.96–1.03)	0.838
VAS PGA TP0	Yes vs. no	0.99 (0.94–1.05)	0.753
TJC TP0		0.87 (0.36–2.09)	0.751
HAQ		2.18 (0.43–11.0)	0.343
PASI		1.03 (0.57–1.85)	0.924
DLQI		1.04 (0.65–1.67)	0.870
BASFI		0.92 (0.57–1.48)	0.739
BASDAI	≥4 vs. <4	0.83 (0.62–1.12)	0.221
Psoriasis onychopathy	Yes vs. no	0.90 (0.21–3.76)	0.883
ESR		1.00 (0.96–1.04)	0.950
CRP		3.22 (0.66–15.63)	0.148
PDUS	Low activity vs. no activity	1.04 (0.48–2.28)	0.912
CEUS	Low enhancement vs. no enhancement	1.61 (0.84–3.09)	0.148
MASEI		1.02 (0.91–1.14)	0.752
Smoke	Yes vs. no	1.09 (0.52–2.25)	0.825
VAS pain at biologic treatment onset	Yes vs. no	1.02 (1.01–1.03)	0.004
HAQ at biologic treatment start		1.89 (0.99–3.61)	0.050
TJC at biologic treatment start		1.05 (1.00–1.12)	0.069
SJC at biologic treatment start		1.07 (1.00–1.16)	0.050

PsA, psoriatic arthritis; BMI, body mass index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; MASEI, Madrid sonography enthesitis index; PASI, Psoriasis Area Severity Index; DLQI, Dermatology Life Quality Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale; PGA, patient-reported global health assessment; TJC/SJC, 66/68-swollen and tender joint counts; PDUS, power Doppler ultrasound; CEUS, contrast-enhanced ultrasound. Bold values represent statistically significant results.